PCR Stock Overview
Designs, produces, and sells chemical products in Poland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
PCC Rokita SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł67.40 |
| 52 Week High | zł109.80 |
| 52 Week Low | zł67.40 |
| Beta | 1.19 |
| 1 Month Change | -7.80% |
| 3 Month Change | -16.06% |
| 1 Year Change | -26.74% |
| 3 Year Change | -23.41% |
| 5 Year Change | 38.97% |
| Change since IPO | 103.26% |
Recent News & Updates
Recent updates
Is There An Opportunity With PCC Rokita SA's (WSE:PCR) 36% Undervaluation?
May 30
Is PCC Rokita (WSE:PCR) Using Too Much Debt?
Aug 24PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 29Is PCC Rokita (WSE:PCR) A Risky Investment?
Jan 18PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23
Apr 16Why We Like The Returns At PCC Rokita (WSE:PCR)
Mar 19What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?
Jan 25We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)
Sep 01Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching
Jun 14Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?
May 18Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The Brakes
Apr 13Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They Seem
Mar 23PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Mar 09Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?
Feb 19
What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?
Feb 04Is PCC Rokita (WSE:PCR) Using Too Much Debt?
Jan 15Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?
Dec 30Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three Years
Dec 17PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Dec 03Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?
Nov 20Shareholder Returns
| PCR | PL Chemicals | PL Market | |
|---|---|---|---|
| 7D | -7.9% | -7.5% | -2.6% |
| 1Y | -26.7% | -25.8% | -4.9% |
Return vs Industry: PCR matched the Polish Chemicals industry which returned -25.8% over the past year.
Return vs Market: PCR underperformed the Polish Market which returned -4.9% over the past year.
Price Volatility
| PCR volatility | |
|---|---|
| PCR Average Weekly Movement | 3.0% |
| Chemicals Industry Average Movement | 4.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in PL Market | 8.7% |
| 10% least volatile stocks in PL Market | 3.2% |
Stable Share Price: PCR has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: PCR's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 907 | Wieslaw Klimkowski | www.pcc.rokita.pl |
PCC Rokita SA designs, produces, and sells chemical products in Poland and internationally. It offers chlorine and alkali; polyurethane insulation systems; household chemicals and cleaning agents; washing preparations; liquid chemicals and disinfectants; vegan body and hair cleansing products; shower gels, hair shampoos, and liquid soaps; foams; and organic products, as well as polyols, naphthalene, and phosphorus derivatives. The company also provides specialty products, including anionic surfactants, alkoxylated fatty alcohols, non-ionic surfactants, synthetic and foam-forming extinguishing agents, synthetic base oils and additives, polyester polyols, chemical raw materials, polyurethane adhesives and prepolymers, polymeric polyols, and polyether polyols.
PCC Rokita SA Fundamentals Summary
| PCR fundamental statistics | |
|---|---|
| Market cap | zł1.34b |
| Earnings (TTM) | zł121.01m |
| Revenue (TTM) | zł2.00b |
11.1x
P/E Ratio0.7x
P/S RatioIs PCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCR income statement (TTM) | |
|---|---|
| Revenue | zł2.00b |
| Cost of Revenue | zł1.59b |
| Gross Profit | zł404.58m |
| Other Expenses | zł283.57m |
| Earnings | zł121.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.10 |
| Gross Margin | 20.28% |
| Net Profit Margin | 6.06% |
| Debt/Equity Ratio | 42.8% |
How did PCR perform over the long term?
See historical performance and comparisonDividends
32.0%
Current Dividend Yield91%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:51 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PCC Rokita SA is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lukasz Prokopiuk | Dom Maklerski Banku Ochrony Srodowiska S.A. |
| Tomasz Duda | Erste Group Bank AG |
| Jakub Szkopek | Erste Group Bank AG |